



Article

Site-Specific Conversion of Cysteine in a Protein to Dehydroalanine Using 2-Nitro-5-thiocyanatobenzoic Acid

Yuchen Qiao ¹ , Ge Yu ¹, Sunshine Z. Leeuwon ¹ and Wenshe Ray Liu ^{1,2,3,4,*} 

¹ The Texas A&M Drug Discovery Laboratory, Department of Chemistry, Texas A&M University, College Station, TX 77843, USA; richyqiao@tamu.edu (Y.Q.); gyu@tamu.edu (G.Y.); sunshineleeuwon@gmail.com (S.Z.L.)

² Department of Biochemistry & Biophysics, Texas A&M University, College Station, TX 77843, USA

³ Molecular & Cellular Medicine Department, College of Medicine, Texas A&M University, College Station, TX 77843, USA

⁴ Institute of Biosciences and Technology and Department of Translational Medical Sciences, College of Medicine, Texas A&M University, Houston, TX 77030, USA

* Correspondence: wliu@chem.tamu.edu; Tel.: +1-979-845-1746

Abstract: Dehydroalanine exists natively in certain proteins and can also be chemically made from the protein cysteine. As a strong Michael acceptor, dehydroalanine in proteins has been explored to undergo reactions with different thiolate reagents for making close analogues of post-translational modifications (PTMs), including a variety of lysine PTMs. The chemical reagent 2-nitro-5-thiocyanatobenzoic acid (NTCB) selectively modifies cysteine to form S-cyano-cysteine, in which the S-C β bond is highly polarized. We explored the labile nature of this bond for triggering E2 elimination to generate dehydroalanine. Our results indicated that when cysteine is at the flexible C-terminal end of a protein, the dehydroalanine formation is highly effective. We produced ubiquitin and ubiquitin-like proteins with a C-terminal dehydroalanine residue with high yields. When cysteine is located at an internal region of a protein, the efficiency of the reaction varies with mainly hydrolysis products observed. Dehydroalanine in proteins such as ubiquitin and ubiquitin-like proteins can serve as probes for studying pathways involving ubiquitin and ubiquitin-like proteins and it is also a starting point to generate proteins with many PTM analogues; therefore, we believe that this NTCB-triggered dehydroalanine formation method will find broad applications in studying ubiquitin and ubiquitin-like protein pathways and the functional annotation of many PTMs in proteins such as histones.

Keywords: cysteine; dehydroalanine; 2-nitro-5-thiocyanatobenzoic acid; NTCB; post-translational modifications



Citation: Qiao, Y.; Yu, G.; Leeuwon, S.Z.; Liu, W.R. Site-Specific Conversion of Cysteine in a Protein to Dehydroalanine Using 2-Nitro-5-thiocyanatobenzoic Acid. *Molecules* **2021**, *26*, 2619. <https://doi.org/10.3390/molecules26092619>

Academic Editors: Luca D. D'Andrea and Lucia De Rosa

Received: 7 April 2021

Accepted: 27 April 2021

Published: 29 April 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.




Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

The currently known genetic code specifies 22 proteinogenic amino acids that are biosynthetically incorporated into proteins during translation. Built upon them, organisms, especially eukaryotes, undergo a plethora of post-translational modifications (PTMs) to impart proteins with a large variety of unique functions. Functional annotation of PTMs requires the synthesis of proteins that contain them. In cells, proteins are usually post-translationally modified via enzymatic reactions. Due to the fact that the enzymes which install PTMs are either unknown or promiscuous, chemical biologists have long been focusing on the development of synthetic and semi-synthetic methods for the synthesis of post-translationally modified proteins for their functional investigations [1–4]. Notable methods include native chemical ligation [5], expressed protein ligation [6], and the genetic code expansion technique that relies on the suppression of amber codon for the incorporation of noncanonical amino acids that are post-translationally modified proteinogenic amino acids themselves, or can be chemically modified to form amino acids

with PTMs [7–11]. Built upon the unique reactivity of the most nucleophilic amino acid, cysteine, methods have also been developed for its conversion to a variety of PTM analogues via both direct conjugation to many electrophiles [12] and chemical conversion to dehydroalanine (Dha) [13]. Dha contains an α , β -unsaturated carbonyl moiety that can undergo both Michael addition and cross coupling reactions to generate PTMs or their analogues [14,15]. Related applications include the functional annotation of histone PTMs [16]. Moreover, Dha in a protein might form a reactive chemical probe for covalent conjugation with associating partners for their identification. Various mono-/poly-ubiquitin (Ub) or ubiquitin-like protein (Ubl)-based Dha probes have been successfully used to capture enzymes functioning in Ub and Ubl pathways [17–20]. Those Ub/Ubl-Dha molecules have also been used for the synthesis of ubiquitinated or Ubl-tagged proteins to discover the selectivity and linkage specificity of deubiquitinases (DUBs) and ubiquitin-like proteases (ULPs) [21–23].

To chemically convert cysteine to Dha in a protein in relatively mild conditions, Davis et al. developed several reagents [14]. Two of them, 2,5-dibromohexanediamide (DBHDA) [14] and methyl 2,5-dibromopentanoate (MDBP) [24], are the most commonly used which selectively convert cysteine to Dha by bis-alkylation and then elimination in the aqueous system (Scheme 1A). Both reagents have been successfully practiced in the synthesis of antibody–drug conjugates and proteins with PTM analogues [14,24,25]. For the efficient conversion of cysteine to Dha when using DBHDA and MDBP, a high pH is typically used to achieve a high yield. Sometimes, a high temperature might also be required [24,25]. There are other methods available, although they generally require harsh conditions that are not compatible with proteins. Dha can also be generated in a protein through the genetic incorporation of an alkylated selenocysteine followed by oxidation and then elimination (Scheme 1B,C), or a phosphoserine followed by elimination (Scheme 1D), as demonstrated by Schultz, Liu, Park, Chen, and their coworkers [26–29]. Another technique called genetically encoded chemical conversion (GECCO), in which serine/threonine is selectively converted to Dha or dehydrobutyrine (Dhb) by the assistance of a proximal, genetically encoded fluorosulfo-tyrosine (FSY) residue, was also reported (Scheme 1E) [30]. In comparison to cysteine modification methods, these latter methods require complicated direct evolution and selection processes of t-RNA synthetases that can specifically incorporate those unnatural amino acids (uAA) into a protein. This genetic code expansion technique usually limits the expression level of those uAA-containing proteins. In this study, we report a simple method that uses the readily available, highly water-soluble 2-nitro-5-thiocyanatobenzoic acid (NTCB) to react with cysteine in a protein for its conversion to Dha under bio-orthogonal conditions at pH 7. This approach is exceedingly selective and efficient when the cysteine is located at a flexible end of a protein compared to the aforementioned methods, which makes it an ideal way to obtain several Ub- and Ubl-based, Dha-containing probes.



Scheme 1. Protein dehydroalanine generation via (A) two bis-alkylation elimination methods that site-specifically convert cysteine to dehydroalanine; (B) oxidative elimination of an arylated selenocysteine; (C) oxidative elimination of an alkylated selenocysteine; (D) basic elimination of a phosphoserine; and (E) genetically encoded chemical conversion, a proximity driven *in vivo* substitution elimination reaction at a serine or threonine residue through the assistance of fluorosulfo-tyrosine.

2. Results

NTCB is a highly reactive reagent that transfers its cyano group rapidly to a nucleophilic thiolate. When it is provided to a protein, it will quickly cyanylate the protein cysteine to form S-cyano-cysteine which undergoes reversible intramolecular addition with the cysteine N-amide to generate 1-acyl-2-iminothiazolidine, an intermediate that can undergo nucleophilic acyl substitution (Figure 1A). By taking advantage of this nucleophilic acyl substitution, we have recently developed a technique termed activated cysteine-directed protein ligation (ACPL) [31]. During the development of ACPL, we noticed that a protein was usually not fully converted to a ligation product. The SDS-PAGE analysis of the reaction showed a protein band that ran at the same place as the original protein (Figure S1). We previously thought that this was the unreacted original

protein. HPLC analysis of products after the ACPL reaction between Ub-G76C-6H and propargylamine (Pa) showed two protein peaks (Figure 1B). Electrospray ionization mass spectrometry (ESI-MS) analysis of Peak 2 indicated the desired product from the ACPL reaction (Figure 1C). However, the deconvoluted ESI-MS spectrum of Peak 1 revealed a molecular weight of 9454.4 Da (Figure 1D) that did not match the theoretical mass of Ub-G76C-6H (9433.7 Da), disproving our original assumption of incomplete conversion of Ub-G76C-6H. This detected molecular weight matches the replacement of the cysteine thiol group in Ub-G76C-6H with propargylamine. This replacement can potentially happen in two possible pathways: the cyanylation of the cysteine thiolate makes it an easy leaving group to undergo an SN2 reaction with propargylamine or the formed thiocyanate–protein adduct undergoes a beta elimination reaction to generate a Dha residue which then reacts with propargylamine via aza-Michael addition (Figure 1E). Dha formation via the beta elimination of *S*-cyano-cysteine was previously predicted and observed at a very low level when NTCB was used to hydrolyze proteins at a high pH [32–34]. We deemed that this beta elimination to generate Dha and then addition with propargylamine is a more probable mechanism for the formation of the Peak 1 protein. Based on the HPLC chromatogram in Figure 1B, the Peak 1 protein is about 40% of the overall final products. This high level of Dha formation is likely due to a relatively milder pH we used to perform the ACPL reaction in comparison to that for the traditional hydrolysis reaction.




Figure 1. (A) Mechanism of ACPL approach using NTCB as a cyanide donor. (B) The HPLC chromatogram of products after the ACPL reaction between Ub-G76C-6H and Pa: * indicates the solvent peak. (C) The deconvoluted and integrated ESI-MS spectrum of Peak 2 of B. The parenthesized number colored in red is the theoretical molecular weight of the conjugation production of Ub-G76Pa (Pa replaces G76C-6H in Ub-G76C-6H). (D) The deconvoluted and integrated ESI-MS spectrum of Peak 1 of B. The parenthesized number colored in red is the theoretical molecular weight of the product in which Pa replaces the thiol group in Ub-G76C-6H. (E) A diagram showing two reaction pathways of a cyanylated Ub-G76C-6H product, one undergoing conjugation with Pa and the other undergoing beta elimination to form Dha and then aza-Michael addition with Pa.

According to the scheme shown in Figure 1E, the substitution with Pa and the beta elimination are two competing reactions. Withdrawing Pa from the reaction will potentially improve the yield toward Dha and also keep Dha intact (Figure 2A). We used Ub-G76C-6H to test this prospect. After incubation in a buffer containing 0.5 mM Tris(2-carboxyethyl)phosphine (TCEP) and 5 mM NTCB at pH 9 and 37 °C overnight, about 80% of Ub-G76C-6H was successfully converted to Ub-G76Dha-6H (Figure 2B and Figure S2, Table 1), confirming an improved Dha formation yield in the absence of a strong amine nucleophile. The major byproduct was determined to be Ub₍₁₋₇₅₎, a hydrolysis product in which a water molecule substituted G76C-6H (Figure 2C). We then further optimized the reaction condition by decreasing the pH value to reduce the undesirable hydrolysis. After overnight incubation, LC-MS analysis of reaction products indicated that as pH decreased, the percentage of Ub-G76Dha-6H kept increasing. The yield ranged from 79.9% to 89.5% (Figures S3–S5, Table 1). The yield was not improved further when pH was decreased from 7 to 6.5; therefore, we selected pH 7 as the standard pH value for further optimization. We then tested the temperature effect on this reaction. Despite the fact that the hydrolysis product diminished significantly when the temperature was reduced, the Dha formation was also dramatically decreased (Table 1, Figures S2, S6 and S7). At 5 °C, the predominant product was the cyanylated intermediate of Ub-G76C-6H (Table 1, Figure 2D). Another minor side product which we observed when reactions were carried out at room or low temperature was a thionitrobenoate (TNB) adduct of Ub-G76C-6H (Figure 2E). The addition of TCEP was to reduce the disulfide bond, such as in the TNB adduct. Its observation indicated that TCEP was exhausted during the overnight incubation process. TNB is a product of the cyanylation step and will form an oxidized dimer when TCEP is exhausted. This dimer will then react with Ub-G76C-6H to form the TNB adduct. Observations we made so far indicated that the decreased hydrolysis did not result from better selectivity but was due to incomplete reactions. Furthermore, reactions were compared under both denatured and native conditions at 37 °C. To improve the beta elimination process, 10 mM pyridine (Py) was also included in the reaction as a non-nucleophilic base. The results showed a better yield in the presence of 10 mM Py under both denatured (6 M guanidine hydrochloride (GndCl)) and native conditions compared to the same reaction conditions without the addition of 10 mM Py (Table 1), confirming that Py improves the beta elimination process. We also observed slightly more Dha product formed under denaturing conditions than under native conditions, possibly because cysteine was less restrained under denatured conditions (Table 1, Figures S8 and S9). It is known that the use of organic solvents will curb hydrolysis. For this reason, we explored how solvent composition influences Dha formation. We made solvent mixtures with different ratios of DMSO to water and performed the Dha formation in the presence of 5 mM NTCB, 0.5 mM TCEP, and 10 mM Py in these solvent mixtures at pH 7 and 37 °C overnight. ESI-MS analysis of reaction products showed that the DMSO percentage increase was correlated with the hydrolysis product decrease (Figures S8, S10–S14), as we expected. However, the addition of DMSO led to a significant amount of the cyanylated Ub-G76C-6H intermediate not being converted into the Dha-containing product (Figures S8, S10–S14). This was contrary to the observation under pure aqueous conditions that typically led to complete conversion of the intermediate. The actual yield of the Dha production formation in the presence of DMSO kept decreasing when the DMSO percentage increased (Table 1). Moreover, a high DMSO percentage also resulted in low protein solubility which made the reaction difficult to perform. Collectively, our results confirmed that the addition of an organic solvent does not improve NTCB-triggered conversion from cysteine to Dha in a protein. Therefore, we concluded that using denatured conditions at pH 7, as well as providing 10 mM pyridine, 0.5 mM TCEP, 5 mM NTCB for a reaction under 37 °C overnight, will provide an effective approach to convert the protein cysteine to Dha.




Figure 2. NTCB induced Dha formation in Ub-G76C-6H. (A) Pathways for the formation of four different possible products when Ub-G76C-6H reacts with NTCB. Deconvoluted ESI-MS spectra of (B) the Dha product Ub-G76Dha-6H, (C) the hydrolysis byproduct Ub₍₁₋₇₅₎, (D) the cyanylated intermediate, Ub-G76C(CN)-6H, and (E) the TNB conjugate Ub-G76C(TNB)-6H. Black lines show the detected monoisotopic mass peaks and their relative intensities. Red lines refer to the calculated theoretical monoisotopic peaks and their relative intensities.

Table 1. Quantitation of NTCB induced Dha formation of Ub-G76C-6H.

Reaction Condition			% Yield		
Buffer	pH	Temp. (°C)	Dha	Hydro	TNB
1 × PBS	9	37	79.9	20.1	0
1 × PBS	8	37	84.4	15.6	0
1 × PBS	7	37	89.3	10.7	0.9
1 × PBS	6.5	37	89.5	10.5	0
1 × PBS	7	23	61.6	4.8	1.5
1 × PBS	7	5	12.2	0.6	10.2
20 mM HEPES, 10 mM Py, 6 M GndCl	7	37	97.8	2.2	0
20 mM HEPES, 10 mM Py	7	37	90.2	9.8	0
20 mM HEPES, 10 mM Py, 20% DMSO	7	37	82.9	7.1	2.3
20 mM HEPES, 10 mM Py, 40% DMSO	7	37	78.3	4.7	3.5
20 mM HEPES, 10 mM Py, 60% DMSO	7	37	76.9	1.8	5.0
20 mM HEPES, 10 mM Py, 80% DMSO	7	37	73.1	0.4	3.5
20 mM HEPES, 10 mM Py, 100% DMSO	7	37	70.5	0	1.9

All reactions contained 200 μ M Ub-G76C-6H, 0.5 mM TCEP and 5 mM NTCB. For the conditions without a specifying DMSO percentage, the solvent that was used was pure water.

In eukaryotic cells, proteins can be post-translationally modified by Ub or Ubl proteins to undergo proteasome degradation or serve as function regulators for a large variety of cellular processes [35–39]. To study pathways involving Ub and Ubls, diverse Ub and Ubl probes have been synthesized and used for various research purposes [3,40–42]. Dha probes which contain an α , β -unsaturated carbonyl structure at the C-terminus of Ub and Ubl proteins are ideal in the formation of covalent adducts with a catalytic cysteine in many enzymes in Ub and Ubl pathways. Mono-Ub, di-Ub, SUMO2, LC3 and NEDD8 based Dha probes have all been successfully synthesized by either intein-based protein semi-synthesis or total synthesis [17,20,43–47]. To simplify the synthesis of these Ub/Ubl-Dha probes, we explored the use of NTCB-triggered Dha formation from cysteine for their generation. We expressed a series of recombinant N-terminal FLAG-tagged and C-terminal 6 \times His-tagged Ubl proteins (FLAG-Ubl-GxC-6H), including NEDD8, MNSF β , GABARAP, GABARAPL2, UFM1, URM1, ISG15 and SUMO1/2/3/4 (Figure 3A). Therein, SUMO1/2/3/4, ISG15 and MNSF β natively contain a cysteine residue in their sequences. To avoid unexpected modification at these cysteines, they were mutated to alanine or serine. ESI-MS analysis of purified proteins showed their expected molecular weights (Figure 3B). These proteins were then used to undergo the conversion of the installed cysteine at the C-terminal glycine position to Dha using the aforementioned optimized conditions. All synthesized Dha-containing products (FLAG-Ubl-GxDha-6H) displayed the expected molecular weights (Figure 3C). The only type of byproducts that we detected was a hydrolysis species (Figures S15–S25) in which the C-terminal 6 \times His tag was cleaved; therefore, all Dha products were easily accumulated and purified by Ni-NTA resin after reactions. In comparison to the intein-based approaches and protein total synthesis, our method is much simpler.




Figure 3. The synthesis of FLAG-Ubl-GxH probes by NTCB-triggered Dha formation from cysteine. **(A)** The structures of different UbIs used. **(B)** The deconvoluted and integrated ESI-MS spectra of 11 recombinant FLAG-Ubl-GxC-6H proteins. **(C)** The deconvoluted and integrated ESI-MS spectra of 11 synthesized FLAG-Ubl-Dha-6H probes. All detected molecular weights agreed well with theoretical values in a deviation range of ± 0.4 Da.

Thus far, all synthesized Dha-containing proteins had Dha at their flexible C-terminal ends. To explore whether our NTCB-triggered Dha formation from cysteine would also work with a cysteine in an internal region of a protein, we mutated seven lysine residues (K6, K11, K27, K29, K33, K48, and K63) separately in Ub, expressed the afforded seven Ub mutants in *E. coli*, and then used them to undergo NTCB-triggered Dha formation. All seven expressed proteins had molecular weights matching perfectly with their theoretical values (Figure 4A and Figures S26–S32). However, reaction products varied accordingly for different cysteine mutants. Surprisingly, ESI-LC-MS analysis showed almost complete hydrolysis, with only a trace amount of Dha formation for the reaction between Ub-K63C and NTCB (Figure 4B, and Figures S33 and S34). For the other six mutants, the detected predominant species had a mass of 8564.6 Da that matched with their corresponding cyanylated intermediates (Figure 4C and Figures S35, S37, S39, S41, S43 and S45). The reaction seemed to be stalled after the cyanylation process. When we switched to using a native condition, the Dha product was still not visible. The only significantly increased peak was for the TNB adduct (Figure 4D and Figures S36, S38, S40, S42, S44 and S46), which is likely due to more oxidized TNB dimer formed in a native condition. The reaction was also not obviously improved when we increased the incubating time or temperature (data not shown). Ub is a highly stable protein with a melting temperature higher than 100 °C; therefore, it is likely that all seven mutants do not fully denature in 6 M GndCl to certain extents. Local structural constraints of the introduced cysteine mutations might have prevented the beta elimination process. More investigations are needed to conclude that NTCB-triggered Dha formation does not work for an internal cysteine in a protein. Nevertheless, our current data support that NTCB-triggered Dha formation from cysteine is highly efficient when the cysteine is placed at a structurally flexible region of a protein.




Figure 4. Shown as an example for seven lysine to cysteine mutants of Ub, structures and their corresponding deconvoluted and integrated ESI-MS spectra of (A) Ub-K33C, (B) the hydrolysis product of Ub-K63C, Ub₍₁₋₆₂₎, (C) the cyanylation intermediate of Ub-K33C, and (D) the TNB adduct of Ub-K33C. In deconvoluted MS spectra, black lines show the detected monoisotopic mass peaks and their relative intensities. Red lines refer to the calculated theoretical monoisotopic peaks and their relative intensity. In integrated MS, experimental and theoretical values are labeled as black and red, respectively.

3. Materials and Methods

3.1. General Materials

Isopropyl β -D-1-thiogalactopyranoside (IPTG) was bought from INDOFINE Chemical Company Inc. (Hillsborough, NJ, USA). Sodium phosphate monobasic, sodium chloride, imidazole, Tris, HEPES and DMSO were all provided by VWR (Radnor, PA, USA). NTCB was purchased from TCI America (Portland, OR, USA). TCEP was obtained from Alfa Aesar (Tewksbury, MA, USA). LC/MS-grade water and acetonitrile for liquid chromatography were both purchased from Fisher Scientific (Waltham, MA, USA) and supplied with 0.1% Optima™ LC/MS-grade formic acid (Fisher Scientific, Waltham, MA, USA). All oligonucleotide primers and DNA sequences used for DNA mutagenesis were synthesized by Integrated DNA Technologies (Coralville, IA, USA). Sanger sequencing was performed by Eton Bioscience Inc. (San Diego, CA, USA).

3.2. Plasmid Construction

The expression vectors containing genes coding Ub-G76C-6H and Ub-K6/11/27/29/33/48/63C were generated by site-directed mutagenesis using pETDuet-1-wild-type Ub as a template [31]. The DNA fragments for all UbIs that contained both an N-terminal FLAG tag and a C-terminal 6 \times His tag were ordered from Integrated DNA Technologies (Coralville, IA, USA) and cloned into pETDuet-1 vector by double digestion and ligation using NdeI and KpnI-HF (New England Biolabs: Ipswich, MA, USA) to afford expression vectors for them. Native cysteines were converted to serine or alanine using site-directed

mutagenesis. All amino acid and DNA sequence information of proteins that are described in this article can be found in the supporting information.

3.3. Recombinant Protein Expression and Purification

The expression of all Ub mutants and FLAG-Ubl proteins were performed according to the protocol described previously [23]. Briefly, overnight culture of each protein was inoculated into 1 L 2xYT medium and allowed to grow at 37 °C until OD₆₀₀ reached 0.6–1.0. Then, 1 mM IPTG was added to induce the expression at 18 °C overnight. Upon saturation, cells were collected by centrifugation (6000 rpm, 20 min, 4 °C) and stored at –80 °C if not lysed directly.

For the purification of seven Ub K to C mutants, the bacterial pellet was resuspended in a Ub lysis buffer (50 mM Tris, 1 mM TCEP, pH 7.8) supplied with 0.2 mg/mL lysozyme (Sigma-Aldrich: St. Louis, MO, USA), and lysed by sonication on ice. The total cell lysate was clarified by centrifugation (10,000 rpm, 30 min, 4 °C) and supernatant was collected. After that, 6 M HCl solution was gradually added into the supernatant with constant stirring to adjust the pH value to 1.5–2. The white precipitate was then removed by centrifugation (10,000 rpm, 30 min, 4 °C) and the pH of the acid purification supernatant was adjusted back to 7.8 using 6 M NaOH and then concentrated using an Amicon stirring filtration system with a 5k MWCO membrane (EMD Millipore, Burlington, MA, USA). Subsequently, each protein was desalted into 50 mM ammonium bicarbonate (ABC) buffer by a HiPrep 26/10 Desalting column (GE Healthcare: Chicago, IL, USA) using an NGC™ chromatography system (Bio-Rad Laboratories: Hercules, CA, USA) and analyzed by 15% SDS-PAGE. The concentration of protein solution was measured by the Pierce™ 660 nm Protein Assay Reagent (Thermo Fisher Scientific: Waltham, MA, USA) and dispensed into 100 nmol aliquots for lyophilization. Eventually, protein pellets were either used for chemical reactions or kept at –80 °C for long-term storage.

For the purification of Ub-G76C-6H, Ni binding buffer (50 mM NaH₂PO₄, 500 mM NaCl, 5 mM imidazole, 1 mM TCEP, pH 7.8) was used instead of the Ub lysis buffer to resuspend and lyse the cell pellet. The subsequent steps are identical to the purification of Ub-KxC until finishing the acid purification. Acid supernatant was directly passed through high-affinity Ni-charged resin (Genescript: Piscataway, NJ, USA) without concentration. The resin was then washed with a Ni washing buffer (50 mM NaH₂PO₄, 500 mM NaCl, 25 mM imidazole, 1 mM TCEP, pH 7.8), and eluted in a 7 mL Ni elution buffer (50 mM NaH₂PO₄, 500 mM NaCl, 300 mM imidazole, 1 mM TCEP, pH 7.8). The following desalting, SDS-PAGE, concentration measurement, lyophilization, and storage were as described above.

The purification of all eleven FLAG-Ubl-GxC-6H proteins, except the involvement of the acid purification part, was performed using the same process as that for Ub-G76C-6H.

3.4. NTCB-Triggered Dha Formation

The stock solutions of 500 mM TCEP and 500 mM NTCB were prepared in water and DMSO, respectively. For all the optimization reactions, each aliquot of 100 nmol Ub-G76C-6H was dissolved in a buffer mentioned in Table 1, followed by adding 0.5 mM TCEP and 5 mM NTCB sequentially. The reactions were then incubated at 5/18/37 °C for 18 h based on the desired testing requirements. Later, each reaction mixture was desalted to a 50 mM ABC buffer using a HiTrap Desalting column (GE Healthcare: Chicago, IL, USA) in the NGC chromatography system to quench the reaction. Fractions corresponding to the peak UV signal without conductivity changes were collected for ESI-LC-MS analysis.

For reactions on eleven FLAG-Ubl-G76C-6H proteins, instead of changing buffer and temperature for each condition, a buffer containing 20 mM HEPES, 10 mM pyridine at pH 7, as well as 37 °C incubation was used constantly for all Ubl proteins. All other conditions were identical, as mentioned above.

For reactions on seven Ub K to C mutants, besides one set of reactions which was set up using the same conditions as for FLAG-Ubl proteins, another series of reactions

using denatured conditions were performed. For that set, the reaction buffer was further supplied with 6 M GndCl (VWR: Radnor, PA, USA) as a denaturant. All other conditions were identical, as mentioned above.

3.5. LC-ESI-MS Analysis

Samples for MS were placed in tube inserts inside HPLC sample vials (Agilent Technologies: Santa Clara, CA, USA) for auto injection. The positive LC-ESI-MS was carried out using a Q Exactive Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) connected to a liquid chromatography instrument. The settings for all ESI-MS data acquisitions are listed in Table 2. For the liquid chromatography, 100% water and 100% acetonitrile, both supplied with 0.1% formic acid, were used as mobile phases A and B, respectively. All protein samples were separated on an Accucore™ 150-C4 analytical HPLC column (150 mm × 2.1 mm, 2.6 μm particle size) (Thermo Fisher Scientific: Waltham, MA, USA). The scan range of the mass spectrometer and the gradient of liquid chromatography applied for each analysis varied according to Table 3.

Table 2. General settings of the Q Exactive Orbitrap ESI-MS.

Mass Spectrometer Parameter	Value
Spray Voltage (+)	3.75 kV
Capillary Temperature	320 °C
Sheath Gas Flow Rate	45
Auxiliary Gas Flow Rate	30
Sweep Gas Flow Rate	0
S-Lens RF level	70
Auxiliary Gas Heat Temperature	30 °C
Ion Source	HESI
Resolution	70,000×
AGC target	3 × 10 ⁶
Maximum Injection Time	150 ms

Table 3. LC-MS method settings.

Protein	Method Duration (min)	Mass Spec Scan Range (m/z)	Gradient (%B)
Ub mutants	55	700–1600	5.1–40 min, 15–35%; 40.1 min, 100%
Ub mutants	40	700–1600	3–20 min, 20–30%; 25.1 min, 100%
Ub mutants	30	700–1600	3.1–20 min, 25–32%; 20.1 min, 100%
SUMO1–4	30	700–1600	3.1–20 min, 25–32%; 20.1 min, 100%
NEDD8	30	700–1600	3.1–20 min, 25–35%; 20.1 min, 100%
MNSFβ	30	700–1600	3.1–20 min, 30–40%; 20.1 min, 100%
UFM1	55	700–1600	5.1–40 min, 25–45%; 40.1 min, 100%
URM1	55	700–1800	7.1–32 min, 30–45%; 37.1 min, 60%; 40 min, 98%
ISG15	30	700–2000	3.1–20 min, 32–42%; 20.1 min, 100%
GABARAP	30	700–1800	3.1–20 min, 27–37%; 20.1 min, 100%
GABARAPL2	30	700–1800	3.1–20 min, 27–37%; 20.1 min, 100%

All abbreviations of Ubl protein which represent the FLAG-Ubl-GxC-6H are described in the main text.

3.6. Mass Spectra Data Processing

ESI-MS raw data were exported as .txt files using the Xcalibur Qual Browser (Version: 4.1.31.9; Thermo Fisher Scientific: Waltham, MA, USA). Deconvolution of each raw file was processed by Bayesian Protein Reconstruction using Analyst™ QS software (Version: 1.1; Applied Biosystems: Foster City, CA, USA). The deconvolution parameters were set as follows: Adduct: hydrogen; Step mass: 0.1 Da; S/N threshold: 20; Minimum intensity (%): 5; Iteration: 20. Start and stop mass were inputted according to the observed mass data of each protein sample. Deconvoluted results were then replotted using GraphPad

Prism (Version: 8.0.2; GraphPad: San Diego, CA, USA) to obtain normalized spectra. After that, normalized deconvoluted results were integrated by a Python script to obtain their experimental averaged mass values. The theoretical monoisotopic peaks distribution and values were calculated using another Python script. All integrated and theoretical data were plotted using GraphPad Prism.

3.7. Product Yield Quantitation

Quantitation of the reaction yield was calculated using the peak areas on the mass intensity chromatogram using the Xcalibur Qual Browser (Version: 4.1.31.9; Thermo Fisher Scientific: Waltham, MA, USA). For example, the yield of Dha product ($Y_{Dha}\%$) was calculated using Equation (1), where A refers to each peak area. Accounting for possible tailing effects and background noise, each peak area only included the space above the line between its beginning and ending. In addition, for peaks that showed up on the previous peak's tailing area, we assumed such contributions were all caused by the detection of new species. Further correction was applied when a single peak contained both Dha product and cyanylation product (where the intensity of the lower signal species was higher than 5% of the intensity of higher signal species). In this case, the ratio of Dha product (R_{Dha}) was quantified as the proportion of its signal intensity (I_{Dha}) over the overall integrated deconvoluted mass spectra of both Dha and cyanylation products using Equation (2). The substitution of A_{Dha} , the numerator in Equation (1), by $A_{Dha} \times R_{Dha}$ led to Equation (3) for calculating the yield of the Dha product.

$$Y_{Dha}\% = \frac{A_{Dha}}{A_{Dha} + A_{hydro} + A_{TNB}} \times 100\% \quad (1)$$

$$R_{Dha} = \frac{I_{Dha}}{I_{Dha} + I_{CN}} \quad (2)$$

$$Y_{Dha}\% = \frac{A_{Dha} \times R_{Dha}}{A_{Dha} + A_{hydro} + A_{TNB}} \times 100\% \quad (3)$$

4. Conclusions

NTCB is a protein-cyanylating reagent which we have used previously for the development of ACPL, a protein ligation technique. By reprogramming NTCB for the generation of Dha from cysteine, we optimized the reaction condition in the presence of a denaturant and a non-nucleophilic base at pH 7. Using a Ub with a cysteine at its flexible C-terminal side, we were able to obtain a Dha-containing product with a yield of close to completion. Applying this same condition to a number of Ubl proteins with a cysteine installed at their flexible C-terminal sides also resulted in their corresponding Dha-containing derivatives. Ub/Ubl-Dha probes are useful in proteomic analyses of cysteine-containing enzymes functioning in Ub and Ubl pathways. Our method dramatically simplifies their synthesis. Its broad adoption for the study of Ub and Ubl pathways is expected. The majority of histone PTMs are found at the flexible N-terminal tail of all four histones. The flexible nature of the histone tails potentiates NTCB-triggered Dha formation from cysteine; therefore, we foresee potential applications of our method in the generation of histones with PTM analogues as well for their functional annotation.

Supplementary Materials: The following are available online, Figures S1–S46, Tables S1 and S2.

Author Contributions: Conceptualization, Y.Q. and W.R.L.; experiment processing and data analysis, Y.Q. and G.Y.; software and Python scripts, Y.Q., S.Z.L. and W.R.L.; writing—original draft preparation, Y.Q.; writing—review and editing, Y.Q., G.Y. and W.R.L.; funding acquisition, W.R.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by National Institutes of Health (Grants R01GM127575 and R01GM121584) and the Welch Foundation (grant A-1715).

Acknowledgments: We thank Yohannes H. Rezenom, the director of Texas A&M University Chemistry Mass Spectrometry Facility, for helping us with the issues during the mass spectrometry analysis.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: All chemicals are commercially available as mentioned in the Materials and Methods part. Plasmids and Python scripts are available upon request from the authors.

References

1. Klemm, T.; Ebert, G.; Calleja, D.J.; Allison, C.C.; Richardson, L.W.; Bernardini, J.P.; Lu, B.G.; Kuchel, N.W.; Grohmann, C.; Shibata, Y.; et al. Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2. *EMBO J.* **2020**, *39*, e106275. [[CrossRef](#)] [[PubMed](#)]
2. Ward, J.A.; McLellan, L.; Stockley, M.; Gibson, K.R.; Whitlock, G.A.; Knights, C.; Harrigan, J.A.; Jacq, X.; Tate, E.W. Quantitative chemical proteomic profiling of ubiquitin specific proteases in intact cancer cells. *ACS Chem. Biol.* **2016**, *11*, 3268–3272. [[CrossRef](#)] [[PubMed](#)]
3. Sui, X.; Wang, Y.; Du, Y.-X.; Liang, L.-J.; Zheng, Q.; Li, Y.-M.; Liu, L. Development and application of ubiquitin-based chemical probes. *Chem. Sci.* **2020**, *11*, 12633–12646. [[CrossRef](#)]
4. Chuh, K.N.; Batt, A.R.; Pratt, M.R. Chemical methods for encoding and decoding of posttranslational modifications. *Cell Chem. Biol.* **2016**, *23*, 86–107. [[CrossRef](#)] [[PubMed](#)]
5. Dawson, P.E.; Muir, T.W.; Clark-Lewis, I.; Kent, S.B. Synthesis of proteins by native chemical ligation. *Science* **1994**, *266*, 776–779. [[CrossRef](#)]
6. Muir, T.W.; Sondhi, D.; Cole, P.A. Expressed protein ligation: A general method for protein engineering. *Proc. Natl. Acad. Sci. USA* **1998**, *95*, 6705–6710. [[CrossRef](#)]
7. Neumann, H.; Peak-Chew, S.Y.; Chin, J.W. Genetically encoding N(epsilon)-acetylysine in recombinant proteins. *Nat. Chem. Biol.* **2008**, *4*, 232–234. [[CrossRef](#)]
8. Nguyen, D.P.; Mahesh, M.; Elsässer, S.J.; Hancock, S.M.; Uttamapinant, C.; Chin, J.W. Genetic encoding of photocaged cysteine allows photoactivation of TEV protease in live mammalian cells. *J. Am. Chem. Soc.* **2014**, *136*, 2240–2243. [[CrossRef](#)]
9. Lee, Y.J.; Wu, B.; Raymond, J.E.; Zeng, Y.; Fang, X.; Wooley, K.L.; Liu, W.R. A genetically encoded acrylamide functionality. *ACS Chem. Biol.* **2013**, *8*, 1664–1670. [[CrossRef](#)]
10. Wang, Z.A.; Kurra, Y.; Wang, X.; Zeng, Y.; Lee, Y.J.; Sharma, V.; Lin, H.; Dai, S.Y.; Liu, W.R. A Versatile Approach for Site-Specific Lysine Acylation in Proteins. *Angew. Chem. Int. Ed.* **2017**, *56*, 1643–1647. [[CrossRef](#)] [[PubMed](#)]
11. Wang, Z.A.; Zeng, Y.; Kurra, Y.; Wang, X.; Tharp, J.M.; Vatansever, E.C.; Hsu, W.W.; Dai, S.; Fang, X.; Liu, W.R. A Genetically Encoded Allylsine for the Synthesis of Proteins with Site-Specific Lysine Dimethylation. *Angew. Chem. Int. Ed.* **2017**, *56*, 212–216. [[CrossRef](#)] [[PubMed](#)]
12. Simon, M.D.; Chu, F.; Racki, L.R.; de la Cruz, C.C.; Burlingame, A.L.; Panning, B.; Narlikar, G.J.; Shokat, K.M. The site-specific installation of methyl-lysine analogs into recombinant histones. *Cell* **2007**, *128*, 1003–1012. [[CrossRef](#)] [[PubMed](#)]
13. Bernardes, G.J.L.; Chalker, J.M.; Errey, J.C.; Davis, B.G. Facile Conversion of Cysteine and Alkyl Cysteines to Dehydroalanine on Protein Surfaces: Versatile and Switchable Access to Functionalized Proteins. *J. Am. Chem. Soc.* **2008**, *130*, 5052–5053. [[CrossRef](#)] [[PubMed](#)]
14. Chalker, J.M.; Gunnoo, S.B.; Boutureira, O.; Gerstberger, S.C.; Fernández-González, M.; Bernardes, G.J.; Griffin, L.; Hailu, H.; Schofield, C.J.; Davis, B.G. Methods for converting cysteine to dehydroalanine on peptides and proteins. *Chem. Sci.* **2011**, *2*, 1666–1676. [[CrossRef](#)]
15. Dadová, J.; Galan, S.R.; Davis, B.G. Synthesis of modified proteins via functionalization of dehydroalanine. *Curr. Opin. Chem. Biol.* **2018**, *46*, 71–81. [[CrossRef](#)] [[PubMed](#)]
16. Wright, T.H.; Bower, B.J.; Chalker, J.M.; Bernardes, G.J.; Wiewiora, R.; Ng, W.L.; Raj, R.; Faulkner, S.; Vallee, M.R.; Phanumartwath, A.; et al. Posttranslational mutagenesis: A chemical strategy for exploring protein side-chain diversity. *Science* **2016**, *354*, 6312. [[CrossRef](#)]
17. Haj-Yahya, N.; Hemantha, H.P.; Meledin, R.; Bondalapati, S.; Seenaiyah, M.; Brik, A. Dehydroalanine-based diubiquitin activity probes. *Org. Lett.* **2014**, *16*, 540–543. [[CrossRef](#)] [[PubMed](#)]
18. Weber, A.; Elliott, P.R.; Pinto-Fernandez, A.; Bonham, S.; Kessler, B.M.; Komander, D.; El Oualid, F.; Krappmann, D. A linear diubiquitin-based probe for efficient and selective detection of the deubiquitinating enzyme OTULIN. *Cell Chem. Biol.* **2017**, *24*, 1299–1313.e7. [[CrossRef](#)]
19. Xu, L.; Fan, J.; Wang, Y.; Zhang, Z.; Fu, Y.; Li, Y.-M.; Shi, J. An activity-based probe developed by a sequential dehydroalanine formation strategy targets HECT E3 ubiquitin ligases. *Chem. Commun.* **2019**, *55*, 7109–7112. [[CrossRef](#)]
20. An, H.; Statsyuk, A.V. Facile synthesis of covalent probes to capture enzymatic intermediates during E1 enzyme catalysis. *Chem. Commun.* **2016**, *52*, 2477–2480. [[CrossRef](#)]
21. Meledin, R.; Mali, S.M.; Singh, S.K.; Brik, A. Protein ubiquitination via dehydroalanine: Development and insights into the diastereoselective 1, 4-addition step. *Org. Biomol. Chem.* **2016**, *14*, 4817–4823. [[CrossRef](#)] [[PubMed](#)]
22. Miseta, A.; Csutora, P. Relationship between the occurrence of cysteine in proteins and the complexity of organisms. *Mol. Biol. Evol.* **2000**, *17*, 1232–1239. [[CrossRef](#)] [[PubMed](#)]

23. Krall, N.; Da Cruz, F.P.; Boutureira, O.; Bernardes, G.J. Site-selective protein-modification chemistry for basic biology and drug development. *Nat. Chem.* **2016**, *8*, 103–113. [[CrossRef](#)]
24. Dadová, J.; Wu, K.-J.; Isenegger, P.G.; Errey, J.C.; Bernardes, G.A.J.; Chalker, J.M.; Raich, L.; Rovira, C.; Davis, B.G. Precise probing of residue roles by post-translational β , γ -C, N aza-Michael mutagenesis in enzyme active sites. *ACS Cent. Sci.* **2017**, *3*, 1168–1173. [[CrossRef](#)] [[PubMed](#)]
25. Freedy, A.M.; Matos, M.J.; Boutureira, O.; Corzana, F.; Guerreiro, A.; Akkapeddi, P.; Somovilla, V.J.; Rodrigues, T.; Nicholls, K.; Xie, B. Chemoselective installation of amine bonds on proteins through aza-Michael ligation. *J. Am. Chem. Soc.* **2017**, *139*, 18365–18375. [[CrossRef](#)]
26. Wang, J.; Schiller, S.M.; Schultz, P.G. A Biosynthetic Route to Dehydroalanine-Containing Proteins. *Angew. Chem. Int. Ed.* **2007**, *46*, 6849–6851. [[CrossRef](#)] [[PubMed](#)]
27. Wang, Z.U.; Wang, Y.S.; Pai, P.J.; Russell, W.K.; Russell, D.H.; Liu, W.R. A facile method to synthesize histones with posttranslational modification mimics. *Biochemistry* **2012**, *51*, 5232–5234. [[CrossRef](#)] [[PubMed](#)]
28. Yang, A.; Ha, S.; Ahn, J.; Kim, R.; Kim, S.; Lee, Y.; Kim, J.; Soll, D.; Lee, H.Y.; Park, H.S. A chemical biology route to site-specific authentic protein modifications. *Science* **2016**, *354*, 623–626. [[CrossRef](#)] [[PubMed](#)]
29. Lin, S.; He, D.; Long, T.; Zhang, S.; Meng, R.; Chen, P.R. Genetically encoded cleavable protein photo-cross-linker. *J. Am. Chem. Soc.* **2014**, *136*, 11860–11863. [[CrossRef](#)]
30. Yang, B.; Wang, N.; Schmier, P.D.; Zheng, F.; Zhu, H.; Polizzi, N.F.; Ittuveetil, A.; Saikam, V.; DeGrado, W.F.; Wang, Q.; et al. Genetically Introducing Biochemically Reactive Amino Acids Dehydroalanine and Dehydrobutyrine in Proteins. *J. Am. Chem. Soc.* **2019**, *141*, 7698–7703. [[CrossRef](#)]
31. Qiao, Y.; Yu, G.; Kratch, K.C.; Wang, X.A.; Wang, W.W.; Leeuwon, S.Z.; Xu, S.; Morse, J.S.; Liu, W.R. Expressed Protein Ligation Without Intein. *J. Am. Chem. Soc.* **2020**, *142*, 7047–7054. [[CrossRef](#)] [[PubMed](#)]
32. Jacobson, G.R.; Schaffer, M.H.; Stark, G.R.; Vanaman, T.C. Specific chemical cleavage in high yield at the amino peptide bonds of cysteine and cystine residues. *J. Biol. Chem.* **1973**, *248*, 6583–6591. [[CrossRef](#)]
33. Degani, Y.; Patchornik, A. Cyanylation of sulfhydryl groups by 2-nitro-5-thiocyanobenzoic acid. High-yield modification and cleavage of peptides at cysteine residues. *Biochemistry* **1974**, *13*, 1–11. [[CrossRef](#)] [[PubMed](#)]
34. Tang, H.-Y.; Speicher, D.W. Identification of alternative products and optimization of 2-nitro-5-thiocyanatobenzoic acid cyanylation and cleavage at cysteine residues. *Anal. Biochem.* **2004**, *334*, 48–61. [[CrossRef](#)]
35. Pickart, C.M.; Eddins, M.J. Ubiquitin: Structures, functions, mechanisms. *Biochim. Biophys. Acta Mol. Cell Res.* **2004**, *1695*, 55–72. [[CrossRef](#)]
36. Hu, H.; Sun, S.-C. Ubiquitin signaling in immune responses. *Cell Res.* **2016**, *26*, 457–483. [[CrossRef](#)] [[PubMed](#)]
37. Deng, L.; Meng, T.; Chen, L.; Wei, W.; Wang, P. The role of ubiquitination in tumorigenesis and targeted drug discovery. *Signal Transduct. Target. Ther.* **2020**, *5*, 1–28. [[CrossRef](#)]
38. Hochstrasser, M. Origin and function of ubiquitin-like proteins. *Nature* **2009**, *458*, 422–429. [[CrossRef](#)]
39. Cappadocia, L.; Lima, C.D. Ubiquitin-like protein conjugation: Structures, chemistry, and mechanism. *Chem. Rev.* **2018**, *118*, 889–918. [[CrossRef](#)]
40. Mali, S.M.; Singh, S.K.; Eid, E.; Brik, A. Ubiquitin signaling: Chemistry comes to the rescue. *J. Am. Chem. Soc.* **2017**, *139*, 4971–4986. [[CrossRef](#)]
41. Love, K.R.; Catic, A.; Schlieker, C.; Ploegh, H.L. Mechanisms, biology and inhibitors of deubiquitinating enzymes. *Nat. Chem. Biol.* **2007**, *3*, 697. [[CrossRef](#)] [[PubMed](#)]
42. Hewings, D.S.; Flygare, J.A.; Bogyo, M.; Wertz, I.E. Activity-based probes for the ubiquitin conjugation–deconjugation machinery: New chemistries, new tools, and new insights. *FEBS J.* **2017**, *284*, 1555–1576. [[CrossRef](#)]
43. Meledin, R.; Mali, S.M.; Kleifeld, O.; Brik, A. Activity-Based Probes Developed by Applying a Sequential Dehydroalanine Formation Strategy to Expressed Proteins Reveal a Potential α -Globin-Modulating Deubiquitinase. *Angew. Chem. Int. Ed.* **2018**, *57*, 5645–5649. [[CrossRef](#)]
44. Jiang, H.-K.; Kurkute, P.; Li, C.-L.; Wang, Y.-H.; Chen, P.-J.; Lin, S.-Y.; Wang, Y.-S. Revealing USP7 Deubiquitinase Substrate Specificity by Unbiased Synthesis of Ubiquitin Tagged SUMO2. *Biochemistry* **2020**, *59*, 3796–3801. [[CrossRef](#)] [[PubMed](#)]
45. Witting, K.F.; Mulder, M.P.; Ova, H. Advancing our understanding of ubiquitination using the Ub-toolkit. *J. Mol. Biol.* **2017**, *429*, 3388–3394. [[CrossRef](#)] [[PubMed](#)]
46. van Wijk, S.J.; Fulda, S.; Dikic, I.; Heilemann, M. Visualizing ubiquitination in mammalian cells. *EMBO Rep.* **2019**, *20*, e46520. [[CrossRef](#)]
47. Mulder, M.P.; Witting, K.; Berlin, I.; Pruneda, J.N.; Wu, K.-P.; Chang, J.-G.; Merckx, R.; Bialas, J.; Groettrup, M.; Vertegaal, A.C. A cascading activity-based probe sequentially targets E1–E2–E3 ubiquitin enzymes. *Nat. Chem. Biol.* **2016**, *12*, 523. [[CrossRef](#)] [[PubMed](#)]